Why is There US Apathy Towards ABPM: Low Reimbursement or Cognitive Dissonance? - Krishna Rocha-Singh, MD, FSCAI

↳ This is a section part of Moment: CRT 2016 Technology & Innovation - Renal Denervation: New Data and Clinical Trial Design Update

Add this Moment to your Passport

Learn from this moment and keep it forever.
No longer available for purchase

Preview

Summary

Why is There US Apathy Towards ABPM: Low Reimbursement or Cognitive Dissonance? presented by Krishna Rocha-Singh, MD, FSCAI at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.
No longer available for purchase

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows
  • Physicians with an interest in Resistant Hypertension

Session Name: Renal Denervation: New Data and Clincal Trial Design Update

Track: Technology & Innovation

Learning Objectives

  • Updates in Renal Denervation and Hypertension Therapies 

Other Components in this Moment

Overview
Long-term Outcome of OUS Renal Denervation Trials - Felix Mahfoud, MD
SYMPLICITY 3 Longterm Outcome and Lessons Learned - Ajay Kirtane, MD, SM
Status of Renal Denervation Studies for Indications Beyond Hypertension, CHF, CKD, Sleep Apnea - Justin Davies, BSc, MBBS, PhD
Update on SPYRAL HTN Global Studies and Rationale for New Study Design - Felix Mahfoud, MD
Update on REINFORCE Study Rationale for Study Design - Michael Weber, MD
ReCor’s Trial Program - Ajay Kirtane, MD, SM
Long-term Outcome and Update on the ENLIGHTEN Study - Vasilios Papademetriou, MD, Dsc
Is There an Unmet Need for Device Treatment for Moderate Hypertension? - Brent Egan, MD
What is the Optimal Device Trial Design for Hypertension Therapy? - Michael Weber, MD
US Preventive Services Task Force Recommendation on ABPM Rationale/ Potential Implications - Michael Weber, MD
How Do I Treat Today’s Patients with Resistant Hypertension in My Practice? - Horst Sievert, MD, FSCAI
What Are the Primary Endpoints for Controlling Hypertension? Office vs. Ambulatory BP - Felix Mahfoud, MD
Why is There US Apathy Towards ABPM: Low Reimbursement or Cognitive Dissonance? - Krishna Rocha-Singh, MD, FSCAI
Cost-effectiveness in Moderate HTN Population - Brent Egan, MD
Loading Simple Education